Overall rank by patents
#28,338
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Cellular Biomedicine Group HK Limited
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, active 2021–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
9
Total patents granted
5
CPC technology areas
9.2
Avg claims per patent
-
5-year filing velocity
The verdict
Cellular holds 9 US patents across 5 technology areas, rank #28,338 of 50,000 tracked assignees.
- #28,338
- of 50,000 US assignees by volume
- Top 51%
- by Innovation Score (34.7/100)
- 9.2
- avg claims per patent
Portfolio overview
Cellular Biomedicine Group HK Limited has been granted 9 US utility patents between 2021 and 2022, placing Cellular Biomedicine Group HK Limited at rank #28,338 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.2 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Cellular Biomedicine Group HK Limited is one of the more focused assignees in the PatentsView dataset. By volume, Cellular sits between CCA And B, Llc (9 patents, rank #28,334) and Center FOR Abrasives AND Refractories Research & Development C.a.r.r.d. Gmbh (9 patents, rank #28,342) - the closest US assignees by grant volume. The composite Innovation Score of 34.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2022, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Cellular Biomedicine Group HK Limited's 9.2 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Cellular Biomedicine Group HK Limited against peers pursuing similar technology classes.
Who files at Cellular's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- CCA and B
CCA and B, LLC
9 patents
- CCCC First Harbor…
CCCC FIRST HARBOR ENGINEERING CO., LTD.
9 patents
- CCS Contractor Eq…
CCS Contractor Equipment &SupplyLLC
9 patents
- Cellomics
CELLOMICS, INC.
9 patents
- Celon Pharma
CELON PHARMA S.A.
9 patents
- Celyad
CELYAD S.A.
9 patents
- Cemedine
CEMEDINE CO., LTD.
9 patents
- Center FOR Abrasi…
CENTER FOR ABRASIVES AND REFRACTORIES RESEARCH & DEVELOPMENT C.A.R.R.D. GMBH
9 patents
- Cellular Biomedic… ◀
CELLULAR BIOMEDICINE GROUP HK LIMITED
9 patents
What this shows Cellular holds 9 patents at rank #28,338, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cellular
By rank, the assignees closest to #28,338 in granted patent volume.
- CCA And B, Llc #28,334 · 9 patents
- CCCC First Harbor Engineering Co., Ltd. #28,335 · 9 patents
- CCS Contractor Equipment &supplyllc #28,336 · 9 patents
- Cellomics, Inc. #28,337 · 9 patents
- Celon Pharma S.a. #28,339 · 9 patents
- Celyad S.a. #28,340 · 9 patents
- Cemedine Co., Ltd. #28,341 · 9 patents
- Center FOR Abrasives AND Refractories Research & Development C.a.r.r.d. Gmbh #28,342 · 9 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Cellular's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Cellular's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 51% higher than 49% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 3 | 33.3% |
| 2022 | 6 | 66.7% |
Which technologies does Cellular Biomedicine Group HK Limited patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Frequently Asked Questions
How many patents does Cellular Biomedicine Group HK Limited hold?
Cellular Biomedicine Group HK Limited holds 9 US granted patents filed between 2021 and 2022, spanning 5 technology areas.
What is Cellular Biomedicine Group HK Limited's Innovation Score?
Cellular Biomedicine Group HK Limited has an Innovation Score of 34.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Cellular Biomedicine Group HK Limited focus on?
Cellular Biomedicine Group HK Limited's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 7 patents. The company has filed patents in 5 CPC subclasses total.
Is Cellular Biomedicine Group HK Limited's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Cellular Biomedicine Group HK Limited.
What does claim depth mean for Cellular Biomedicine Group HK Limited's patents?
Cellular Biomedicine Group HK Limited's patents average 9.2 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Cellular Biomedicine Group HK Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Cellular's 9 grants land it in the top 51% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Cellular ranks #28,338 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.